US › Healthcare

Theravance Biopharma Inc (TBPH)

US · Healthcare · Biotechnology

$16.88+0.06%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$17.7M
Revenue YoY
+15.0%
Net profit
$-4.9M
Profit YoY
+63.7%
EPS
$0.01
EPS estimate
$0.09
Net margin
-27.9%

EPS came in at 0.01 against a street estimate of 0.09 — a miss of 88.9%.

Key statistics

Market cap
$873.8M
P/E
7.6
Forward P/E
7.9
P/B
3.01
Book value
$5.64
EPS (TTM)
$2.23
52-week high
$21.03
52-week low
$10.82
50-day MA
$16.69
200-day MA
$17.05
Beta
0.17

Analyst view

Analysts rate Theravance Biopharma Inc a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $17.67.

Shareholding

Insiders
4.68%
Institutions
98.45%

Largest institutional holders

FundStake
Madison Avenue Partners, LP18.35%
Weiss Asset Management LP14.39%
Newtyn Management LLC9.34%
BlackRock Inc8.29%
Irenic Capital Management LP5.33%
Vanguard Capital Management, LLC3.44%
State Street Corp2.50%
Acadian Asset Management LLC2.46%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Theravance Biopharma Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.